LoQus23 Therapeutics

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

DDW Highlights: 13 January 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a new report found breast cancer was the world’s most studied disease… Read More

#Podcasts

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

This week in Drug Discovery (5 – 9 January) 

News round-up for 5 – 9 January by Bruno Quinney, Content Team at DDW.  This week in DDW, a new report finds breast cancer is the world’s most studied disease for the fifth year running. That same report predicts obesity to break into the top five, with weight loss a key theme across… Read More

#News

Neuronal inclusions in Huntington’s disease
#Biotech #Huntington's disease #LoQus23 Therapeutics

Groundbreaking Huntington’s disease drug set for development 

Biotechnology company LoQus23 Therapeutics has nominated its drug candidate LQT-23 for development as a treatment for Huntington’s Disease (HD).  LQT-23 is a first-in-class oral drug candidate which has shown potential to slow or stop the progression of HD. The candidate works as an allosteric small molecule inhibitor… Read More

#News

Neuronal inclusions in Huntington’s disease
#Financing #Huntington's disease #LoQus23 Therapeutics #Neurodegenerative disorders

New therapy for Huntington’s disease gets £35 million boost

Biotechnology company LoQus23 Therapeutics has closed its £35 million (c.$43 million) Series A financing. The financing round was led by Forbion, alongside existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF). Forbion General Partner Rogier Rooswinkel will join LoQus23’s Board of Directors. LoQus23 was founded… Read More

#Business & Investment #News